How to buy Cogstate (CGS) shares

Cogstate Limited is a health information services business based in Australia. Cogstate shares (CGS) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cogstate has a trailing 12-month revenue of around $28.8 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Cogstate

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Cogstate. Find the share by name or ticker symbol: CGS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cogstate reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Cogstate. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cogstate stock price (ASX:CGS)

Share Trading Account Offer

IG Share Trading

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian shares, international shares, forex and CFD trading

• Monthly fee: $0.00
• Brokerage fee - standard trade: $8.00 or 0.1%
• International: Yes
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

Sort by:

Name	Product	Standard brokerage fee	Inactivity fee	Markets
IG Share Trading Finder Award		AUD $8 or 0.1%	$50 per quarter if you make fewer than three trades in that period	ASX shares, Global shares	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
Superhero share trading		AUD $5	No	ASX shares, US shares, ETFs	Australia’s lowest-cost broker for ASX shares and ETFs. Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.	Go to site More Info	Compare	loading Fetching your data...
Bell Direct Share Trading Finder AwardExclusive		AUD $15	No	ASX shares, mFunds, ETFs	⭐ Finder Exclusive: Get 5 free stock trades and unlimited ETF trades until July 31, 2021 when you join Bell Direct. Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.	Go to site More Info	Compare	loading Fetching your data...
Saxo Capital Markets (Classic account) Finder Award		AUD $6.99	No	ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs	Acess 19,000+ stocks on 37 exchanges worldwide Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.	Go to site More Info	Compare	loading Fetching your data...

loading

Prev

1

Next

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy Cogstate stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Cogstate under- or over-valued?

Valuing Cogstate stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cogstate's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cogstate's P/E ratio

Cogstate's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 183x. In other words, Cogstate shares trade at around 183x recent earnings.

That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Cogstate's EBITDA

Cogstate's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.5 million.

The EBITDA is a measure of a Cogstate's overall financial performance and is widely used to measure a its profitability.

Cogstate share dividends

We're not expecting Cogstate to pay a dividend over the next 12 months.

Have Cogstate's shares ever split?

Cogstate's shares were split on 5 August 2008.

Cogstate share price volatility

Over the last 12 months, Cogstate's shares have ranged in value from as little as $0.535 up to $1.655. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cogstate's is -0.2812. This would suggest that Cogstate's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cogstate has bucked the trend.

Cogstate overview

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations across various indications, including Alzheimer's disease, HIV, multiple sclerosis, pediatric and adult oncology, Parkinson's disease, epilepsy, and schizophrenia. As of June 30, 2020, it had participated in approximately 1,800 academic research studies in approximately 200 indications. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is based in Fitzroy, Australia.

Stocks similar to Cogstate

Pro Medicus Limited

A$56.83

-A$1.52 (-2.61%)

Alcidion Group Limited

A$0.39

+A$0.03 (8.45%)

Mach7 Technologies Limited

A$0.98

-A$0.03 (-2.99%)

MedAdvisor Limited

A$0.34

+A$0.03 (9.84%)

Frequently asked questions

• What percentage of Cogstate is owned by insiders or institutions?

  Currently 50.127% of Cogstate shares are held by insiders and 35.216% by institutions.

• When does the fiscal year end for Cogstate?

  Cogstate's fiscal year ends in June.

• Where is Cogstate based?

  Cogstate's address is: 425 Smith Street, Fitzroy, VIC, Australia, 3065

• What is Cogstate's ISIN number?

  Cogstate's international securities identification number is: AU000000CGS8